Daiwa Securities Group Inc. Has $60,000 Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Daiwa Securities Group Inc. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 80.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,151 shares of the company’s stock after acquiring an additional 2,299 shares during the period. Daiwa Securities Group Inc.’s holdings in Intellia Therapeutics were worth $60,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Atria Investments Inc increased its stake in Intellia Therapeutics by 24.3% in the 3rd quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock valued at $475,000 after buying an additional 4,511 shares during the last quarter. KBC Group NV increased its stake in Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares during the last quarter. Quest Partners LLC increased its stake in Intellia Therapeutics by 181.6% in the 3rd quarter. Quest Partners LLC now owns 19,748 shares of the company’s stock valued at $406,000 after buying an additional 12,734 shares during the last quarter. LMR Partners LLP increased its stake in Intellia Therapeutics by 35.3% in the 3rd quarter. LMR Partners LLP now owns 71,100 shares of the company’s stock valued at $1,461,000 after buying an additional 18,533 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in Intellia Therapeutics by 21.6% in the 3rd quarter. Jennison Associates LLC now owns 47,899 shares of the company’s stock valued at $984,000 after buying an additional 8,497 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 29,000 shares of company stock worth $352,551 in the last three months. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $9.58 on Tuesday. Intellia Therapeutics, Inc. has a 1 year low of $8.30 and a 1 year high of $28.54. The stock has a market capitalization of $991.69 million, a PE ratio of -1.76 and a beta of 1.97. The company’s 50 day simple moving average is $10.30 and its two-hundred day simple moving average is $14.50.

Wall Street Analyst Weigh In

Several research firms have commented on NTLA. The Goldman Sachs Group reiterated a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. Citigroup increased their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Barclays reduced their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.